Deciding to try TMS means agreeing to let magnetic pulses change how your brain works. That's not a small thing to sign up for, and wanting to know what that means for your brain in the long run is both sensible and wise.
If you've been researching this online, you've probably encountered two completely different pictures:
Somewhere between those two extremes, you're trying to work out what's actually true.
This article shares what the research shows about the long-term safety of TMS, how long the benefits realistically last, and what the evidence says about what happens if symptoms eventually return, including where the data is still limited and what we don't yet fully know.
Below, we cover:
Transcranial magnetic stimulation works by delivering magnetic pulses through the scalp to induce small electrical currents in targeted regions of the brain. Those currents trigger increased blood flow in the area and an increase in neurotransmitter activity. Nothing foreign enters the brain; TMS works entirely by activating resources that are already there. Think of it less as introducing something new and more as prompting the brain to make better use of what it already has.
It’s important to understand that not all TMS is the same. The term transcranial magnetic stimulation covers several protocols that differ in pulse pattern, session length, and treatment schedule. Standard repetitive TMS (rTMS) delivers pulses once daily over four to six weeks.
Newer accelerated protocols, including SAINT™ TMS, condense the same total dose into days rather than weeks, using a pulse pattern called intermittent theta burst stimulation (iTBS) that allows sessions to be completed in roughly ten minutes instead of thirty to forty. This article addresses TMS broadly where the safety and mechanism data apply across protocols, and calls out specific protocol differences where they matter, particularly around durability.
Same total stimulation dose, different delivery
Session length
30–40 min
Conventional pulse delivery
Sessions per day
1 session
Once daily
Treatment duration
4–6 weeks
20–30 sessions total
Pulse pattern
Repetitive
Standard frequency pulses
Session length
~10 min
Theta burst pattern
Sessions per day
10 sessions
Spaced throughout the day
Treatment duration
5 days
50 sessions total
Pulse pattern
Theta burst
Mimics the brain's natural rhythms
Both protocols deliver equivalent total stimulation. Accelerated iTBS condenses the course into days rather than weeks.
The leading explanation for why iTBS works faster is that the theta burst pattern mimics a rhythm the brain naturally produces during learning and memory consolidation. The brain appears to recognize and respond to this pattern more efficiently than conventional pulse delivery, which may be why accelerated iTBS protocols can achieve in days what standard rTMS takes weeks to produce.
One thing that often worries patients is that the treatment feels much harsher than it actually is. The trigeminal nerve, which carries pain signals from your sinuses and teeth, runs close to the scalp and gets activated during TMS sessions. That's what causes the jaw clenching, headaches, and scalp discomfort that patients often describe as jarring.
What TMS actually feels like from session to session is covered in detail in our previous article. The short version: it can cause an unpleasant peripheral sensation, but it’s temporary and has nothing to do with what's happening in the brain itself.
It also helps to understand what TMS is actually targeting in the depressed brain. Depression is associated with measurable disorganization of neural activity in the prefrontal cortex circuits responsible for mood regulation. In people without depression, this region acts like a regulatory switch that can dial down runaway negative thinking when needed. In major depression, that switch weakens. TMS doesn't introduce a new circuit; it strengthens the one that's already there but not working properly, helping to restore normal brain function.
This is also why "TMS reorganizes your brain" is a misleading frame, even though it's commonly used. TMS doesn't restructure a healthy brain. It gives a disorganized brain the neuroplastic conditions to consolidate back toward how it's designed to work. A more accurate way to think about it: TMS isn't reorganizing your brain, it's organizing it.
Transcranial magnetic stimulation has been studied as a treatment of depression for decades. Its path to FDA approval in 2008 required comprehensive adverse event reporting across large clinical populations, and that reporting has continued in the years since. In all of that accumulated data, no controlled study has documented lasting neurological damage as a reproducible outcome.
The most common side effects of TMS are short-term and relatively mild:
Some patients also report tinnitus or migraines, particularly in the early treatment sessions.
Serious side effects are rare. The most significant is seizure, which occurs in fewer than 1 in 10,000 treatment sessions. The risk of seizure is higher in patients with a history of seizures or epilepsy, which is why those conditions are standard contraindications. Other contraindications include certain metallic implants near the treatment site (cochlear implants and aneurysm clips in particular), as the magnetic fields generated during treatment can interfere with these devices. A thorough screening by your healthcare provider before starting any TMS treatment course should catch these factors.
There's also a deeper reason to be reassured about long-term safety, which comes down to basic neuroscience. TMS stimulation can only increase neuronal functionality; there is no known physiological mechanism by which it reduces it. When you stimulate areas of the brain with TMS, you increase blood flow and make nerve cells in that area more responsive. None of those processes have a mechanism for causing harm.
Even if the coil is placed over a less-than-ideal region, the result is increased function in that region, not damage. The worst-case outcome of a TMS treatment course is that it doesn't improve your depressive symptoms.
Headache · Scalp discomfort · Jaw clenching · Muscle twitching · Brief lightheadedness
Caused by trigeminal nerve activation near the scalp, not by effects on the brain itself
Tinnitus · Migraines
Most often reported during the first few sessions and diminish with continued treatment
Seizure
Risk is higher in patients with seizure history, which is a standard contraindication
Across decades of clinical research, no controlled study has documented lasting neurological damage from TMS as a reproducible outcome.
These accounts exist online on Reddit and Facebook, and patients are right to bring them up.
The honest answer is that these experiences are not reflected in controlled clinical trial data across thousands of patients. Clinical trials are specifically designed to detect harm; they require reporting of all adverse events, not just the positive outcomes. If lasting neurological damage from TMS were a real and reproducible phenomenon, it would show up in that data. It has not.
One well-established contributor to this kind of reporting is something called attribution bias. Highly salient, visceral events (and TMS treatment is certainly that) are psychologically easy to blame for subsequent difficulties, even when there's no causal link. If someone goes through an intense five-day treatment and then experiences a difficult period afterward, the treatment becomes the obvious explanation, whether or not it's actually responsible.
That's not a dismissal of anyone's suffering. It's an honest account of why subjective reports and objective clinical data sometimes diverge, and why the absence of this pattern in controlled data is significant. If you're concerned about whether TMS can worsen depression, that question is addressed directly in a separate article.
TMS is also not appropriate for everyone. Patients with bipolar disorder, for example, require careful psychiatric evaluation before starting TMS. That’s not because TMS is inherently dangerous in these cases, but because depressive symptoms in bipolar disorder respond differently to brain stimulation than those in major depressive disorder, and treatment planning should account for that. A qualified psychiatrist should always be involved in that assessment.
Some patients notice their symptoms worsen briefly during or just after treatment before improvement consolidates. This is a real and documented phenomenon, and it should not be confused with long-term side effects. The TMS dip, as it's commonly called, affects roughly 20–25% of patients, typically appearing after the second or third session.
Neuroplastic change involves a transitional period where the brain is consolidating toward a new stable state, and that process isn't always linear. Symptoms may fluctuate during it, but do not permanently worsen. The consolidation period passes, and for the majority of patients who experience it, improvement follows.
Before you start treatment, it’s worth discussing this possibility with your treatment team so it doesn't catch you off guard. Knowing it can happen, and that it's a sign the brain is responding rather than that something has gone wrong, makes a significant difference in how patients experience and interpret that window.
Among patients who respond to a TMS treatment course, the majority maintain improvement for several months. By the one-year mark, however, a substantial proportion have experienced some degree of symptom return. For most people, that's a gradual drift rather than a sudden crash, and it typically responds well to follow-up treatment.
For SAINT-based accelerated TMS specifically, there's an important caveat: the protocol is newer (roughly five years old). The original proof-of-concept work established that a condensed schedule of fMRI-guided theta burst stimulation could produce rapid remission in patients with treatment-resistant depression who had failed multiple prior antidepressant medications, a result that was replicated in a subsequent double-blind randomized controlled trial. But longer-term follow-up data is still accumulating compared to repetitive transcranial magnetic stimulation (rTMS), which has decades of clinical trials behind it.
What studies so far show is that around 33% of patients remain in full remission at twelve weeks without any further treatment, with the average duration of improvement running roughly fifteen weeks. A separate study tracking repeated SAINT courses found that 9 out of 10 patients who relapsed after their first course achieved remission again with a second, which showed how well the brain retains its responsiveness to the protocol across multiple rounds.
That 33% number is lower than the initial remission rate. The five-day protocol produces a powerful initial response, but without any follow-up plan in place, a significant proportion of patients experience symptom return within a few months.
More encouraging is what happens when follow-up is proactive. When patients were monitored after their initial course and received brief booster sessions at the first signs of symptom return, 86% maintained remission across a full twelve months. The gap between 33% and 86% is almost entirely explained by whether follow-up care was absent or active. Therefore, TMS often works best as part of an ongoing care relationship, rather than a one-time intervention.
Remission rates at 12 months for SAINT-based accelerated TMS
33%
Still in full remission
at 12 weeks
86%
Maintained remission
across 12 full months
The difference between a treatment that fades and one that lasts is almost entirely explained by whether follow-up care is in place.
Sources: Geoly et al., Brain Stimulation 2025 · Stimpson et al., Brain Stimulation 2025
Relapse after TMS is also rarely a full return to where you started. For many patients, it's a partial drift toward more difficult days rather than a return to the depths of treatment-resistant depression. The brain doesn't become resistant to TMS the way it can become resistant to antidepressant medications.
Patients who respond to an initial course tend to respond again to retreatment, often more quickly and with fewer sessions required. There is also early evidence that repeated courses may have a cumulative benefit, with each round building on the neuroplastic changes of the last.
The timing of retreatment changes the outcome
Initial TMS remission achieved → Symptoms begin to drift
Wait and see
Step 1
Mild symptoms return
Sleep disruption, lower motivation
Step 2
Full depressive episode re-establishes
Weeks to months of worsening
Step 3
Full retreatment course needed
Another 5-day protocol
Harder, longer, costlier recovery
Act early
Step 1
Mild symptoms return
Sleep disruption, lower motivation
Step 2
Brief booster session (1–2 days)
Brain responds quickly from familiarity
Step 3
Remission restored and maintained
86% maintained remission at 12 months
Faster return to remission, lower cost
Symptom return is often not a sign that the treatment failed. TMS maintenance sessions are typically much shorter than the initial course. Most patients who need retreatment after a SAINT-based protocol require just one to two days rather than a full five-day course to return to remission. The brain's familiarity with the treatment means it takes less to restore the effect.
The timing of retreatment matters significantly. The evidence strongly supports returning at the first signs of symptom drift rather than waiting for depression to fully re-establish. Research on monitored follow-up found that patients who received brief intervention when early warning signs appeared maintained remission at dramatically higher rates than those who waited. Catching a drift early is a fundamentally different clinical situation from retreating a full relapse.
Ongoing mood monitoring after TMS is key. Knowing what your personal early warning signs look like and having a clear plan for what to do when they appear is as important to long-term outcomes as the treatment itself. Patients who stay in contact with their clinician and act early on symptom return consistently do better than those who don't.
Continued therapy alongside TMS, particularly cognitive behavioral therapy (CBT), also supports how long results last. CBT helps build the thinking patterns and habits that reinforce what TMS does neurologically, and patients who stay in therapy after treatment tend to sustain benefits longer than those who treat the end of TMS sessions as the end of active care. If you're wondering whether your antidepressant medications aren't working and TMS might be the next step, this article covers how the two approaches compare and interact.
Standard rTMS produces full remission in roughly 30% of patients. The gap between that number and what's possible with more precise protocols comes down to two compounding factors: how accurately the right brain region is targeted, and how completely the treatment is delivered. Both matter not just for initial outcomes but for how long those outcomes hold.
Unlike electroconvulsive therapy (ECT)—the other major brain stimulation treatment for severe or treatment-resistant depression—TMS is noninvasive, requires no anesthesia, produces no memory loss, and carries no risk of the cognitive impairment associated with ECT.
It also differs from other neuromodulation approaches like vagus nerve stimulation and deep TMS in its targeting precision and delivery speed.
Cognitive FX's accelerated fMRI-guided TMS directly addresses both targeting and completeness. Before any stimulation begins, a functional MRI maps each patient's individual brain activity to locate the precise stimulation target in the prefrontal cortex, to within 1–2mm accuracy. Standard landmark-based rTMS has a margin of error of up to 2cm. That difference matters: consistently hitting the right spot is what produces the kind of complete, stable neural change that holds up over time. FDA-approved neuronavigation then ensures the same location is reached reliably across all 50 treatment sessions of the five-day course.
| Standard rTMS | Cognitive FX (fMRI-Guided) | |
|---|---|---|
| Targeting method | Anatomical landmarks on the scalp; margin of error up to 2cm | fMRI maps individual brain activity; accuracy within 1–2mm |
| Session navigation | Manual coil placement; varies session to session | FDA-approved neuronavigation; same exact spot every session |
| Schedule | 1 session/day over 4–6 weeks | 50 sessions in 5 days (equivalent total dose) |
| Pulse type | Standard repetitive pulses; 30–40 min per session | Intermittent theta burst (iTBS); ~10 min per session |
| CBT included | Typically not part of TMS protocol | Built into treatment week; improves remission rates ~19% |
| Remission rate | ~30% full remission | ~79% remission with fMRI-guided targeting |
| Booster plan | Varies by clinic; often no formal follow-up | fMRI data carries forward; booster day included in pricing |
| Cost | Often covered by insurance | $7,000–$12,000 (self-pay); vs. $30,000+ for Magnus SAINT™ |
CFX's program is an off-label equivalent of the SAINT protocol, not the licensed Magnus SAINT™ product. Protocols are equivalent in dosage, equipment, and schedule.
Cognitive behavioral therapy is built into the treatment week alongside TMS sessions, which improves remission rates by approximately 19% compared to TMS alone and supports sustained improvement after the week of treatment ends.
For patients who do experience symptom return, the fMRI targeting data from the initial treatment carries forward, so no new scan is required for booster sessions. That keeps the cost and logistical burden of retreatment substantially lower. A booster day is included in the initial treatment pricing, with discounted retreatment available beyond that.
Cognitive FX's treatment runs $7,000 to $12,000, compared to $30,000 or more for the licensed Magnus SAINT™ product. Standard rTMS remains covered by most major insurers for qualifying patients; the accelerated protocol is currently self-pay.
Cognitive FX's program is an off-label equivalent of the SAINT protocol, not the licensed Magnus SAINT™ product, using the same dosage, schedule, and iTBS delivery, with fMRI analysis performed in-house by Cognitive FX's neuroscientist and physician rather than through proprietary software.
Decades of research and comprehensive adverse event reporting have produced no evidence of lasting neurological harm. The durability picture is more honest than most TMS marketing acknowledges, but the data also shows that the difference between a treatment that fades and one that lasts comes down largely to whether proactive follow-up care is in place. Go in with realistic expectations, know your early warning signs, stay in therapy, and choose a treatment precise enough to give you the best possible foundation from the start.
To understand whether you're a likely candidate for this treatment, or what a realistic long-term plan might look like for your specific history, you can take a short quiz or call 385-334-6093 to speak with someone directly.
Dr. Mark D. Allen holds a Ph.D. in Cognitive Science from Johns Hopkins University and received post-doctoral training in Cognitive Neuroscience and Functional Neuroimaging at the University of Washington. As a co-founder of Cognitive Fx, he played a pivotal role in establishing the unique and exceptional treatment approach. Dr. Allen is renowned for his pioneering work in adapting fMRI for clinical use. His contributions encompass neuroimaging biomarkers development for post-concussion diagnosis and innovative research into the pathophysiology of chronic post-concussion symptoms. He's conducted over 10,000 individualized fMRI patient assessments and crafted a high-intensity interval training program for neuronal and cerebrovascular recovery. Dr. Allen has also co-engineered a machine learning-based neuroanatomical discovery tool and advanced fMRI analysis techniques, ensuring more reliable analysis for concussion patients.
With the original form of TMS therapy for major depressive disorder—known as repetitive transcranial magnetic stimulation (rTMS)—some patients begin noticing improvements within the first week of...
How long the effects of TMS last — what researchers call its "durability," meaning how long the benefits of TMS persist after treatment ends — isn't a single statistic. It depends significantly on...
While antidepressant medications remain the most common first-line treatment for depression, research shows they only work for about one-third of patients and often come with unpleasant side effects...
Transcranial magnetic stimulation (TMS) has been FDA-approved for treating major depressive disorder (MDD) since 2008 and is a well-established treatment option, especially for patients who haven’t...
Transcranial magnetic stimulation (TMS) is an established treatment to help patients struggling with major depressive disorder, obsessive-compulsive disorder (OCD), and other mental health conditions.
Although transcranial magnetic stimulation (TMS) has been used for over 20 years and FDA-approved for treating major depressive disorder since 2008, it remains relatively less well-known among the...
